A study to compare the use of low-dose liraglutide in patients without a diagnosis for type 2 diabetes to the other GLP-1 receptor agonists (GLP-1 RAs, albiglutide, dulaglutide, and exenatide)

Trial Profile

A study to compare the use of low-dose liraglutide in patients without a diagnosis for type 2 diabetes to the other GLP-1 receptor agonists (GLP-1 RAs, albiglutide, dulaglutide, and exenatide)

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Liraglutide (Primary) ; Albiglutide; Dulaglutide; Exenatide
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Oct 2017 New trial record
    • 12 Oct 2017 Results presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top